Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA) in a report published on Friday,Benzinga reports. The firm currently has a $32.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q1 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.13) EPS.

Separately, Piper Sandler reduced their target price on Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.60.

Iovance Biotherapeutics Trading Down 19.4 %

IOVA stock opened at $4.24 on Friday. The company has a market capitalization of $1.29 billion, a P/E ratio of -2.85 and a beta of 0.53. Iovance Biotherapeutics has a twelve month low of $3.62 and a twelve month high of $18.24. The business has a 50 day simple moving average of $6.21 and a 200-day simple moving average of $8.55.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million during the quarter, compared to the consensus estimate of $72.17 million. Research analysts predict that Iovance Biotherapeutics will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Iovance Biotherapeutics during the 4th quarter worth about $515,000. Jennison Associates LLC acquired a new position in shares of Iovance Biotherapeutics in the 4th quarter valued at about $493,000. Barclays PLC lifted its position in Iovance Biotherapeutics by 118.8% during the 3rd quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock worth $5,677,000 after acquiring an additional 328,284 shares in the last quarter. Principal Financial Group Inc. lifted its position in Iovance Biotherapeutics by 59.0% during the 3rd quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock worth $37,872,000 after acquiring an additional 1,496,941 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Iovance Biotherapeutics during the 3rd quarter worth approximately $920,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.